BR112016013961A2 - angiotensina ii sozinha ou em combinação para o tratamento da hipotensão - Google Patents

angiotensina ii sozinha ou em combinação para o tratamento da hipotensão

Info

Publication number
BR112016013961A2
BR112016013961A2 BR112016013961A BR112016013961A BR112016013961A2 BR 112016013961 A2 BR112016013961 A2 BR 112016013961A2 BR 112016013961 A BR112016013961 A BR 112016013961A BR 112016013961 A BR112016013961 A BR 112016013961A BR 112016013961 A2 BR112016013961 A2 BR 112016013961A2
Authority
BR
Brazil
Prior art keywords
angiotensin
mcg
norepinephrine
equivalent
treatment
Prior art date
Application number
BR112016013961A
Other languages
English (en)
Portuguese (pt)
Inventor
Chawla Lakhmir
Original Assignee
The George Washington Univ A Congressional Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016013961(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington Univ A Congressional Chartered Not For Profit Corporation filed Critical The George Washington Univ A Congressional Chartered Not For Profit Corporation
Publication of BR112016013961A2 publication Critical patent/BR112016013961A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112016013961A 2013-12-18 2014-12-18 angiotensina ii sozinha ou em combinação para o tratamento da hipotensão BR112016013961A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
PCT/US2014/071186 WO2015095535A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
BR112016013961A2 true BR112016013961A2 (pt) 2017-10-10

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013961A BR112016013961A2 (pt) 2013-12-18 2014-12-18 angiotensina ii sozinha ou em combinação para o tratamento da hipotensão

Country Status (25)

Country Link
US (7) US9220745B2 (https=)
EP (2) EP3607962B1 (https=)
JP (4) JP6824739B2 (https=)
KR (4) KR20220028125A (https=)
CN (4) CN119700926A (https=)
AU (3) AU2014364528C1 (https=)
BR (1) BR112016013961A2 (https=)
CA (1) CA2933601A1 (https=)
CY (1) CY1122604T1 (https=)
DK (2) DK3607962T3 (https=)
EA (1) EA037823B1 (https=)
ES (2) ES3055611T3 (https=)
FI (1) FI3607962T3 (https=)
HR (2) HRP20200009T1 (https=)
HU (1) HUE047062T2 (https=)
IL (1) IL246162B (https=)
LT (2) LT2986308T (https=)
MX (2) MX380968B (https=)
NZ (1) NZ721089A (https=)
PL (2) PL2986308T3 (https=)
PT (2) PT3607962T (https=)
RS (2) RS67626B1 (https=)
SI (2) SI3607962T1 (https=)
SM (2) SMT202500427T1 (https=)
WO (1) WO2015095535A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
PL2986308T3 (pl) 2013-12-18 2020-05-18 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotensyna ii w połączeniu do leczenia niedociśnienia
WO2016007589A1 (en) * 2014-07-08 2016-01-14 La Jolla Pharmaceutical Company Methods for treating hypotension
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
PL3400000T3 (pl) * 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
EP3400001A1 (en) * 2016-01-07 2018-11-14 La Jolla Pharmaceutical Company Methods of administering vasopressors
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
WO2023244552A1 (en) * 2022-06-15 2023-12-21 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
EP4633658A1 (en) * 2022-12-12 2025-10-22 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US6592865B2 (en) 2001-06-04 2003-07-15 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
WO2005044313A2 (en) 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
US20070072817A1 (en) 2005-09-29 2007-03-29 Fibrogen, Inc. Methods for reducing blood pressure
JP2009521513A (ja) 2005-12-30 2009-06-04 ハワード・フロレイ・インスティチュート・オブ・エクスペリメンタル・フィスィオロジー・アンド・メディシン 治療の方法
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
WO2008059062A1 (en) 2006-11-17 2008-05-22 Da Volterra Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP2988770A4 (en) 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
PL2986308T3 (pl) 2013-12-18 2020-05-18 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotensyna ii w połączeniu do leczenia niedociśnienia
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
WO2016007589A1 (en) 2014-07-08 2016-01-14 La Jolla Pharmaceutical Company Methods for treating hypotension
EP3400001A1 (en) 2016-01-07 2018-11-14 La Jolla Pharmaceutical Company Methods of administering vasopressors
PL3400000T3 (pl) 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
JP6824739B2 (ja) 2021-02-03
CN112546197A (zh) 2021-03-26
RS59804B1 (sr) 2020-02-28
US20150164980A1 (en) 2015-06-18
CN106061493A (zh) 2016-10-26
EP2986308A1 (en) 2016-02-24
US20180193407A1 (en) 2018-07-12
PL3607962T3 (pl) 2026-03-09
PT2986308T (pt) 2020-01-21
AU2014364528A9 (en) 2016-07-28
US20160129072A1 (en) 2016-05-12
US10493124B2 (en) 2019-12-03
ES3055611T3 (en) 2026-02-13
EP3607962A1 (en) 2020-02-12
WO2015095535A9 (en) 2016-07-14
SMT202000018T1 (it) 2020-03-13
US20190328827A1 (en) 2019-10-31
LT2986308T (lt) 2020-03-25
CN111920939A (zh) 2020-11-13
WO2015095535A1 (en) 2015-06-25
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
SMT202500427T1 (it) 2026-01-12
JP2025114753A (ja) 2025-08-05
AU2020277230A1 (en) 2020-12-24
US9220745B2 (en) 2015-12-29
KR102399383B1 (ko) 2022-05-19
AU2014364528A1 (en) 2016-06-30
EA037823B1 (ru) 2021-05-25
FI3607962T3 (fi) 2025-11-24
SI3607962T1 (sl) 2026-02-27
IL246162A0 (en) 2016-07-31
ES2771749T3 (es) 2020-07-07
MX2020011190A (es) 2020-11-13
NZ721089A (en) 2022-10-28
KR20220028125A (ko) 2022-03-08
EA201691258A1 (ru) 2016-11-30
CN119700926A (zh) 2025-03-28
HRP20251406T1 (hr) 2026-02-27
AU2014364528B2 (en) 2020-08-27
IL246162B (en) 2020-03-31
JP2022137224A (ja) 2022-09-21
DK2986308T3 (en) 2020-01-27
RS67626B1 (sr) 2026-02-27
KR20240154702A (ko) 2024-10-25
MX2016008108A (es) 2017-03-09
US11559559B2 (en) 2023-01-24
AU2024219851A1 (en) 2024-10-10
JP2017501154A (ja) 2017-01-12
US10765722B2 (en) 2020-09-08
US20190070250A1 (en) 2019-03-07
JP2019214610A (ja) 2019-12-19
HRP20200009T1 (hr) 2020-03-20
LT3607962T (lt) 2026-01-12
HUE047062T2 (hu) 2020-04-28
CY1122604T1 (el) 2021-03-12
AU2014364528C1 (en) 2021-01-07
PL2986308T3 (pl) 2020-05-18
EP3607962B1 (en) 2025-08-13
EP2986308A4 (en) 2017-01-11
JP7175506B2 (ja) 2022-11-21
US10028995B2 (en) 2018-07-24
DK3607962T3 (da) 2025-11-17
SI2986308T1 (sl) 2020-03-31
PT3607962T (pt) 2025-11-18
US20220047669A1 (en) 2022-02-17
CA2933601A1 (en) 2015-06-25
KR20230051721A (ko) 2023-04-18
EP2986308B1 (en) 2019-10-16
US20230226141A1 (en) 2023-07-20
MX380968B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
BR112016013961A2 (pt) angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
BR112016002781A2 (pt) métodos e dispositivos para puncionar tecido
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112018016341A2 (pt) solução de bloqueio do cateter e terapia de bloqueio do cateter
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
BR112015022197A2 (pt) tratamento de cataplexia
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112015020918A2 (pt) métodos para tratar o hcv
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
PH12015502655A1 (en) Method
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
BR112015026973A2 (pt) uso de vanoxerina no tratamento de arritmia cardíaca
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
WO2015069656A8 (en) Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
BR112015021363A2 (pt) adrenérgico alfa-2 para tratamento pressão intraocular e doenças oculares através de vias intravítreas e intracamerais
BR112015028334A2 (pt) agente e método para o tratamento de herpes
BR112018017167A2 (pt) titulação de cebranopadol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]